Filing Details
- Accession Number:
- 0001415889-23-001209
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-19 17:07:31
- Reporting Period:
- 2023-01-17
- Accepted Time:
- 2023-01-19 17:07:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1159036 | Halozyme Therapeutics Inc. | HALO | Biological Products, (No Disgnostic Substances) (2836) | 880488686 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1528185 | Helen Torley | C/O Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-17 | 10,000 | $14.66 | 597,177 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-17 | 8,897 | $50.40 | 588,280 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-01-17 | 1,103 | $50.93 | 587,177 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-01-18 | 10,000 | $14.66 | 597,177 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-18 | 10,000 | $51.05 | 587,177 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-01-19 | 10,000 | $14.66 | 597,177 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-19 | 10,000 | $52.41 | 587,177 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option to Purchase Common Stock | Disposition | 2023-01-17 | 10,000 | $14.66 | 10,000 | $14.66 |
| Common Stock | Option to Purchase Common Stock | Disposition | 2023-01-18 | 10,000 | $14.66 | 10,000 | $14.66 |
| Common Stock | Option to Purchase Common Stock | Disposition | 2023-01-19 | 10,000 | $14.66 | 10,000 | $14.66 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 80,000 | 2024-01-06 | No | 4 | M | Direct | |
| 70,000 | 2024-01-06 | No | 4 | M | Direct | |
| 60,000 | 2024-01-06 | No | 4 | M | Direct |
Footnotes
- The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 7, 2022 in accordance with Rule 10b5-1.
- Represents a weighted average sales price per share. The shares were sold at prices ranging from $49.89 to $50.85. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.89 to $50.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.75 to $51.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.13 to $52.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.
Billionaire Hedge Funds
